Several studies have shown that circulating S100B protein levels are elevated in schizophrenia. 1 This finding has been specifically attributed to glial pathology, as S100B is produced by astro-and oligodendroglial cells and is thought to act as a neurotrophic factor with effects on synaptogenesis, dopaminergic and glutamatergic neutrotransmission. 2 However, this study suggests that overweight and insulin resistance may be alternatively responsible.
Adipose tissue has already been highlighted by others as an important extracerebral source of S100B, as it contains considerable amounts of S100B.
3,4 S100B secretion from adipocytes is reduced by insulin and is activated by physiological factors such as stress and fasting. 5, 6 Therefore, weight gain or adipocyte dysfunction, including insulin insensitivity, could offer important alternative explanations for elevated S100B levels, given the increased prevalence of metabolic syndrome in schizophrenic patients and their firstdegree relatives. 7 The assumption of such extracerebral origins of altered S100B levels in schizophrenia is challenged by findings of elevated S100B in cerebrospinal fluid and postmortem brain tissue. 8, 9 However, glial abnormalities in S100B release may also be caused by disrupted energy supply, as suggested by earlier cell culture studies. 2 Accordingly, impaired insulin signaling has been observed in the dorsolateral prefrontal cortex of schizophrenic patients. 10 Consequently, altered peripheral and cerebral glucose usage is an important factor to be studied to clarify its relation to S100B in schizophrenia. Our study thus assessed S100B in both medicated and drug-free schizophrenic patients, along with body mass index (BMI), measures of glucose usage and adipokine levels.
After obtaining written informed consent, serum samples were taken from 26 patients with acute paranoid schizophrenia (according to DSM-IV, 17 men/9 women, age 34.7 ± 11.3 years, BMI 27.7 ± 5.7, 16 smokers/10 nonsmokers) and from 32 matched controls (20 men/12 women, age 34.4 ± 10.8, BMI 24.3 ± 3.8, 14 smokers/18 nonsmokers). Eleven patients were unmedicated for X6 weeks; 15 were treated with atypical antipsychotics for 26 ± 21 days. Psychopathology was monitored using the positive and negative syndrome scale. Exclusion criteria consisted of an earlier history of immune diseases, immunomodulating treatment, cancer, chronic terminal disease, cardiovascular disorders, diabetes, substance abuse and severe trauma. Only control cases without a past or family history of neuropsychiatric disorders were included.
Blood was collected between 9:00 and 11:00 AM. S100B was measured immunoluminometrically (LIAISON S100, DiaSorin, Dietzenbach, Germany). LINCOplex human adipokine panels A and B (Millipore Corporation, Billerica, MA, USA) were used for the determination of leptin, monocyte chemotactic protein 1, hepatocyte growth factor (HGF), resistin and active plasminogen activator inhibitor 1. Glucose and triglycerides were measured by commercial enzymatic methods. Levels of cotinine, an estimate of tobacco exposure, were quantified by enzymelinked immunosorbent assay (Calbiotech, Spring Valley, CA, USA). Parametric two-tailed tests were applied because of normal distribution of data (Pearson's correlation, ANCOVA with covariates 'BMI' and 'cotinine level', unpaired t-test).
Schizophrenic patients showed elevated S100B levels (F(1,55) = 6.675, P = 0.012) and impaired insulin sensitivity, as indicated by increased glucose (F(1,55) = 13.785, P < 0.001), C-peptide (F(1,55) = 10.578, P = 0.002) and C-peptide/glucose ratios (F(1,55) = 8.238, P = 0.006). In medicated schizophrenic patients, S100B and BMI were elevated (P = 0.041/P < 0.001), but controls with a BMIX25 were also found to show increased S100B levels (T(1,30) = 2.366, P = 0.025). Moreover, in healthy controls, BMI (r = 0.540, P = 0.001), adipokines (leptin: r = 0.545, P = 0.001, HGF: r = 0.441, P = 0.012, resistin: r = 0.377, P = 0.033) and C-peptide/glucose ratios (r = 0.432, P = 0.014) predicted S100B levels. However, in schizophrenic patients, S100B was elevated in both unmedicated (P = 0.049, closely BMI-matched subgroup: P = 0.028) and medicated patients (P = 0.041). Similarly, the finding of insulin resistance, as assessed by C-peptide/glucose ratios, persisted in unmedicated (P = 0.016, closely BMImatched subgroup: P = 0.015) and medicated patients (P = 0.038). Figure 1 illustrates the results.
Our results are suggestive of primary insulin resistance in schizophrenia, resulting in an increased release of S100B from brain and adipose tissue, independent of BMI. The commonly observed weight gain on neuroleptic treatment, however, occurs on the basis of an increased metabolic vulnerability in patients because of medication-independent primary insulin resistance. Future studies in larger samples may focus on drug-naive schizophrenic subjects and the comparison of different standardized treatment regimens to further elucidate the suggested link between S100B and abnormal energy metabolism. The six genome-wide association studies (GWAS) completed in bipolar disorder (BD) [1] [2] [3] [4] [5] [6] have revealed some promising association signals that have been replicated in independent study samples, 7 but the mechanism by which these genes increase disease susceptibility has remained unresolved. Here, our goal was (i) to replicate the best results from the study by Sklar et al., 2008 4 and also the highest ranking imputed SNPs from the WTCCC study 1 and (ii) to define the effect of the Figure 1 Elevated S100B serum concentrations (a) and an increased C-peptide/glucose ratio (b), indicating insulin resistance, were schizophrenia related. Increased BMI was primarily a consequence of antipsychotic medication and not a source of elevated S100B (c). Data are given as means with 95% confidence intervals. Only P-values of significant group differences are displayed.
